NASH and Hepatic Fibrosis
Non- Alcoholic Hepatic Fibrosis
❖ ~16.5M patients in US with NASH
❖ 3M with liver cirrhosis due to NASH
❖ No curative Rx to date
❖ Leading cause for liver transplantation
❖ US ARDS market size $2.9B annually
❖ NASH growing at ~3% per year, large unmet need
❖ Market Opportunity
❖ No FDA-Approved NASH-Specific Therapy
❖Saroglitazar (India)- PPAR agonist, insulin sensitizer
